GCP-Service International West GmbH

The first patient with lower-risk myelodysplastic syndromes (LR-MDS) has been dosed with RVU120 in the phase 2 REMARK study. RVU120, a novel CDK8/19 inhibitor, aims to improve anemia in LR-MDS patients who have exhausted treatment options. The study, conducted by the EMSCO network, includes up to 25 sites globally and plans to enroll up to 40 patients. Primary end points are safety, efficacy, and erythroid response, with secondary end points including transfusion independence and quality of life.